Literature DB >> 2731984

Modulation of endotoxin lethality in mice by hydrazine sulfate.

R Silverstein1, C A Christoffersen, D C Morrison.   

Abstract

Although the precise mechanism of endotoxin lethality has yet to be defined, it is well recognized that the amount of hepatic phosphoenolpyruvate carboxykinase is reproducibly and significantly reduced after challenge with endotoxin. Hydrazine has been shown to be a specific inhibitor of gluconeogenesis, causing a metabolic crossover at the step catalyzed by phosphoenolpyruvate carboxykinase. More recently, it has also been shown that hydrazine sulfate may be of potential therapeutic value against cancer cachexia. The experiments described in this paper demonstrate that treatment of CF1 mice with hydrazine sulfate 5 h prior to challenge with endotoxin from Salmonella enteritidis significantly improved survival. Furthermore, such treatment counteracted the drop in hepatic phosphoenolpyruvate carboxykinase activity in isolated cytosol otherwise evident at 6 h and 12 h after endotoxin challenge. Despite this, there was no corresponding improvement in the plasma glucose, measured at 6, 12, and 24 h following endotoxin challenge. It is suggested that the endogenous response to the metabolic crossover initiated by hydrazine may contribute to the protection. The response to hydrazine sulfate has yet to be fully elaborated but does include the increase in phosphoenolpyruvate carboxykinase activity. In contrast with the protection seen upon hydrazine sulfate pretreatment, injecting a corresponding dose of hydrazine sulfate after the endotoxin resulted in more fatalities.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2731984      PMCID: PMC313843          DOI: 10.1128/iai.57.7.2072-2078.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

1.  Regulation of gluconeogenesis at phosphoenolpyruvate carboxykinase.

Authors:  H Lardy; P E Hughes
Journal:  Curr Top Cell Regul       Date:  1984

2.  Rate-limiting steps in metabolic pathways.

Authors:  R Rognstad
Journal:  J Biol Chem       Date:  1979-03-25       Impact factor: 5.157

3.  Inactivation and modification of phosphoenolpyruvate carboxykinase differentially labeled with bromopyruvate.

Authors:  R Silverstein; C C Lin; K W Fanning; B T Hung
Journal:  Biochim Biophys Acta       Date:  1980-08-07

4.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

Authors:  B Beutler; I W Milsark; A C Cerami
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

5.  Influence of endotoxin treatment on dexamethasone induction of hepatic phosphoenolpyruvate carboxykinase.

Authors:  R E McCallum; T W Seale; R D Stith
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

6.  Influence of hydrazine sulfate on abnormal carbohydrate metabolism in cancer patients with weight loss.

Authors:  R T Chlebowski; D Heber; B Richardson; J B Block
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

7.  Rapid changes in the concentration of phosphoenolpyruvate carboxykinase mRNA in rat liver and kidney. Effects of insulin and cyclic AMP.

Authors:  M A Cimbala; W H Lamers; K Nelson; J E Monahan; H Yoo-Warren; R W Hanson
Journal:  J Biol Chem       Date:  1982-07-10       Impact factor: 5.157

8.  Identity of tumour necrosis factor and the macrophage-secreted factor cachectin.

Authors:  B Beutler; D Greenwald; J D Hulmes; M Chang; Y C Pan; J Mathison; R Ulevitch; A Cerami
Journal:  Nature       Date:  1985 Aug 8-14       Impact factor: 49.962

9.  Inhibition of transcription of the phosphoenolpyruvate carboxykinase gene by insulin.

Authors:  D Granner; T Andreone; K Sasaki; E Beale
Journal:  Nature       Date:  1983 Oct 6-12       Impact factor: 49.962

10.  Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli.

Authors:  E J Ziegler; J A McCutchan; J Fierer; M P Glauser; J C Sadoff; H Douglas; A I Braude
Journal:  N Engl J Med       Date:  1982-11-11       Impact factor: 91.245

View more
  11 in total

1.  Roles of interleukin-1 and tumor necrosis factor in lipopolysaccharide-induced hypoglycemia.

Authors:  S N Vogel; B E Henricson; R Neta
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

Review 2.  Unconventional therapies for cancer: 4. Hydrazine sulfate. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative.

Authors:  E Kaegi
Journal:  CMAJ       Date:  1998-05-19       Impact factor: 8.262

3.  In vivo effects of the antiglucocorticoid RU 486 on glucocorticoid and cytokine responses to Escherichia coli endotoxin.

Authors:  A S Hawes; C S Rock; C V Keogh; S F Lowry; S E Calvano
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

4.  Lipopolyamines: novel antiendotoxin compounds that reduce mortality in experimental sepsis caused by gram-negative bacteria.

Authors:  S A David; R Silverstein; C R Amura; T Kielian; D C Morrison
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

5.  Isoniazid protects mice against endotoxin lethality without influencing tumor necrosis factor synthesis and release.

Authors:  R Urbaschek; D N Männel; R Urbanczik
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

6.  Endogenous and exogenous glucocorticoids have different roles in modulating endotoxin lethality in D-galactosamine-sensitized mice.

Authors:  J C Gonzalez; D C Johnson; D C Morrison; M A Freudenberg; C Galanos; R Silverstein
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

Review 7.  Is the pharmacological treatment of cancer cachexia possible?

Authors:  E Bruera
Journal:  Support Care Cancer       Date:  1993-11       Impact factor: 3.603

8.  Murine tissues exposed to cytotoxic drugs display altered patterns of Candida albicans adhesion.

Authors:  J L López-Ribot; C S McVay; W L Chaffin
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

9.  Identification of tumor necrosis factor as a transcriptional regulator of the phosphoenolpyruvate carboxykinase gene following endotoxin treatment of mice.

Authors:  M R Hill; R E McCallum
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

10.  Virulence of Wolinella recta in a murine abscess model.

Authors:  L Kesavalu; S C Holt; R R Crawley; R Borinski; J L Ebersole
Journal:  Infect Immun       Date:  1991-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.